RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 No Resistance and Improved Renal and Bone Profiles with a Single-Table Regimen of D/C/F/TAF
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 28
SP 22
OP 22
DO 10.1177/155989771428014
UL http://mdc.sagepub.com/content/14/28/22.abstract
AB Darunavir is a protease inhibitor (PI) dosed as a single daily tablet. PIs have a high genetic barrier to resistance, but a PI-based single-tablet regimen has not been available. This article presents the results of the week 48 analysis of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-Boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naïve Adults [GS-US-299-0102; NCT01565850].